Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 185 million in issue proceeds.
The subscription price was determined to SEK 18.50 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates.
Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, William Kåge and Clara Sohlberg.
